Long COVID is characterized by symptoms persisting for at least two months following a SARS-CoV-2 infection, with approximately 65 million individuals affected globally. Currently, no approved treatments exist for this condition. Researchers are investigating a variety of therapeutic options, including structured rehabilitation, antivirals, blood thinners, and anti-inflammatory medications, among others.
The underlying mechanisms of long COVID appear to involve multiple biological factors. These may include persistent viral remnants, low-grade inflammation, and the formation of microclots. Additionally, issues such as autoimmunity, gut microbiome disruptions, and mitochondrial dysfunction have been implicated in the condition's manifestation, which can affect various organs and lead to symptoms like fatigue, cardiovascular issues, and neurological complications.
For those experiencing mild symptoms, non-drug interventions are typically recommended first. Evidence suggests that online rehabilitation programs, breathing exercises, and gradual physical activity can enhance quality of life. However, unmonitored exercise may exacerbate symptoms, necessitating tailored approaches.
Antiviral treatments administered early in the course of COVID-19 may reduce the risk of developing long COVID. In clinical studies, certain antivirals have demonstrated success in diminishing long COVID incidence among high-risk populations.
Additionally, targeted medications are being explored for specific complications arising from long COVID. These include treatments for clotting disorders and immune system imbalances. Research into inflammation reduction has gained momentum, with some medications showing promise in lowering long COVID risk when initiated shortly after infection.
As the scientific community continues to pursue effective therapies, the need for rigorous clinical trials remains critical. Current strategies emphasize a multifaceted approach, blending early antivirals, personalized rehabilitation, and symptom-targeted treatments, while researchers seek more definitive answers regarding long COVID’s complexities.